giovedì 10 settembre 2020

COVID-19 THE RUSSIAN VACCINE IS ALREADY AVAILABLE WITH ALL THE DATA. IF YOU WANT TO BUY IT, GO TO THE OFFICIAL WEBSITE - SOON AVAILABLE COVID-19 THE RUSSIAN VACCINE IS ALREADY AVAILABLE WITH ALL THE DATA. IF YOU WANT TO BUY IT, GO TO THE OFFICIAL WEBSITE - SOON AVAILABLE

 Currently there are about 165 different vaccines for COVID-19 under development worldwide. The main types of vaccines include vector vaccines, inactivated, nucleic acid-based (DNA and mRNA) and protein-based recombinant vaccines. 

The Russian adenovirus vector-based vaccine was registered by the Russian Ministry of Health on August 11 and became the first COVID-19 vaccine registered on the market.

 The announcement created a so-called "Sputnik moment" for the global community. In 1957 the successful launch of the first space satellite by the Soviet Union reinvigorated space research around the world.

 The new Russian vaccine COVID-19 is therefore called Sputnik V. This site was created to provide accurate and up-to-date information about Sputnik V and to combat the disinformation campaign launched against it by the international media. 

 Registration certificate of the Russian Ministry of Health Before the start of clinical trials the vaccine had gone through all stages of pre-clinical trials with experiments on different types of animals, including 2 types of primates. 

 Phase 1 and 2 clinical trials of the vaccine were completed on August 1, 2020. All volunteers felt well, no unexpected or unwanted side effects were observed. The vaccine induced a strong antibody and a cellular immune response. 

No single participant in the current clinical trials was infected with COVID-19 after being administered with the vaccine. The high efficacy of the vaccine has been confirmed by high-precision testing for antibodies in volunteer blood serum (including testing for antibodies that neutralize the coronavirus), as well as the ability of volunteer immune cells to activate in response to the coronavirus S spike protein, which indicates both antibody formation and cellular immune response to the vaccine.

 Post-registration clinical trials involving more than 40,000 people in Russia will begin in one week starting August 24. 

A number of countries, such as the United Arab Emirates, Saudi Arabia, the Philippines and perhaps India or Brazil will join Sputnik V clinical trials locally. 

The vaccine received a certificate of registration from the Russian Ministry of Health on August 11 and according to the emergency rules adopted during the COVID-19 pandemic can be used to vaccinate the population in Russia. 

Mass production of the vaccine should begin in September 2020. The unique substance of Sputnik V and the method of use has patent protection in Russia, obtained by Gamaleya National Research Institute of Epidemiology and Microbiology.

 Clinical trials of Sputnik V. An open study on the safety, tolerability and immunogenicity of the vaccine "Gam-COVID-Vac Lyo" against COVID-19 An open study on the safety, tolerability and immunogenicity of the vaccine drug "Gam-COVID-Vac" against COVID-19 Clinical study on the efficacy, safety and immunogenicity of the vaccine Gam-COVID-Vac against COVID-19 (RESIST)

https://sputnikvaccine.com/

Coronavirus, Lancet: il vaccino della Russia produce anticorpi


0 commenti:

Posta un commento